Cubist Systematic Strategies LLC Decreases Stake in GoodRx Holdings, Inc. (NASDAQ:GDRX)

Cubist Systematic Strategies LLC cut its stake in GoodRx Holdings, Inc. (NASDAQ:GDRX - Free Report) by 97.5% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 12,446 shares of the company's stock after selling 479,249 shares during the period. Cubist Systematic Strategies LLC's holdings in GoodRx were worth $97,000 at the end of the most recent quarter.

Other hedge funds have also recently made changes to their positions in the company. Beacon Capital Management LLC bought a new position in shares of GoodRx in the first quarter worth about $28,000. Plato Investment Management Ltd bought a new position in GoodRx during the 2nd quarter worth about $43,000. Dark Forest Capital Management LP bought a new position in GoodRx during the 2nd quarter worth about $86,000. EntryPoint Capital LLC grew its holdings in GoodRx by 165.2% during the 1st quarter. EntryPoint Capital LLC now owns 18,538 shares of the company's stock worth $132,000 after acquiring an additional 11,548 shares in the last quarter. Finally, Deerfield Management Company L.P. Series C bought a new position in GoodRx during the 2nd quarter worth about $173,000. 63.77% of the stock is currently owned by institutional investors.

Insider Transactions at GoodRx

In other news, major shareholder Equity Vii L.P. Spectrum sold 10,677 shares of the firm's stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $7.86, for a total transaction of $83,921.22. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 4.17% of the company's stock.

Analysts Set New Price Targets

Several research analysts have issued reports on GDRX shares. Citigroup dropped their target price on shares of GoodRx from $11.00 to $10.00 and set a "buy" rating on the stock in a report on Friday, August 9th. Raymond James upgraded shares of GoodRx from an "outperform" rating to a "strong-buy" rating and set a $10.00 target price on the stock in a report on Friday, August 9th. Royal Bank of Canada reiterated an "outperform" rating and set a $10.00 target price on shares of GoodRx in a report on Friday, August 16th. Finally, UBS Group decreased their price target on shares of GoodRx from $9.00 to $8.50 and set a "neutral" rating for the company in a research report on Friday, August 9th. One research analyst has rated the stock with a sell rating, four have issued a hold rating, nine have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $9.36.

GoodRx Stock Performance

NASDAQ:GDRX traded down $0.04 during midday trading on Wednesday, hitting $6.92. The company's stock had a trading volume of 637,469 shares, compared to its average volume of 1,406,576. GoodRx Holdings, Inc. has a fifty-two week low of $4.14 and a fifty-two week high of $9.26. The firm's 50 day moving average is $7.38 and its 200-day moving average is $7.58. The company has a debt-to-equity ratio of 0.96, a current ratio of 7.32 and a quick ratio of 7.32. The firm has a market cap of $2.60 billion, a P/E ratio of -705.00, a P/E/G ratio of 4.44 and a beta of 1.37.

GoodRx (NASDAQ:GDRX - Get Free Report) last issued its quarterly earnings data on Thursday, August 8th. The company reported $0.08 EPS for the quarter, missing analysts' consensus estimates of $0.09 by ($0.01). The firm had revenue of $200.60 million for the quarter, compared to analyst estimates of $200.47 million. GoodRx had a positive return on equity of 3.63% and a negative net margin of 7.57%. GoodRx's revenue for the quarter was up 5.7% compared to the same quarter last year. During the same period in the previous year, the business earned $0.02 EPS. Equities analysts anticipate that GoodRx Holdings, Inc. will post 0.14 earnings per share for the current fiscal year.

GoodRx Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.